Systematic identification of signaling pathways with potential to confer anticancer drug resistance.

Autor:	Martz CA; Department of Pharmacology and Cancer Biology, Duke University, 450 Research Drive, Durham, NC 27710, USA., Ottina KA; Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA. Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA., Singleton KR; Department of Pharmacology and Cancer Biology, Duke University, 450 Research Drive, Durham, NC 27710, USA., Jasper JS; Department of Pharmacology and Cancer Biology, Duke University, 450 Research Drive, Durham, NC 27710, USA., Wardell SE; Department of Pharmacology and Cancer Biology, Duke University, 450 Research Drive, Durham, NC 27710, USA., Peraza-Penton A; Department of Pharmacology and Cancer Biology, Duke University, 450 Research Drive, Durham, NC 27710, USA., Anderson GR; Department of Pharmacology and Cancer Biology, Duke University, 450 Research Drive, Durham, NC 27710, USA., Winter PS; Department of Pharmacology and Cancer Biology, Duke University, 450 Research Drive, Durham, NC 27710, USA., Wang T; Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA. Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA. Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA., Alley HM; Department of Pharmacology and Cancer Biology, Duke University, 450 Research Drive, Durham, NC 27710, USA., Kwong LN; University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA., Cooper ZA; University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA., Tetzlaff M; University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA., Chen PL; University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA., Rathmell JC; Department of Pharmacology and Cancer Biology, Duke University, 450 Research Drive, Durham, NC 27710, USA., Flaherty KT; Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA., Wargo JA; University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA., McDonnell DP; Department of Pharmacology and Cancer Biology, Duke University, 450 Research Drive, Durham, NC 27710, USA., Sabatini DM; Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA. Howard Hughes Medical Institute, Department of Biology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA. Broad Institute, 7 Cambridge Center, Cambridge, MA 02142, USA. sabatini@wi.mit.edu kris.wood@duke.edu., Wood KC; Department of Pharmacology and Cancer Biology, Duke University, 450 Research Drive, Durham, NC 27710, USA. sabatini@wi.mit.edu kris.wood@duke.edu.
Jazyk:	angličtina
Zdroj:	Science signaling [Sci Signal] 2014 Dec 23; Vol. 7 (357), pp. ra121. Date of Electronic Publication: 2014 Dec 23.
DOI:	10.1126/scisignal.aaa1877
Abstrakt:	Cancer cells can activate diverse signaling pathways to evade the cytotoxic action of drugs. We created and screened a library of barcoded pathway-activating mutant complementary DNAs to identify those that enhanced the survival of cancer cells in the presence of 13 clinically relevant, targeted therapies. We found that activation of the RAS-MAPK (mitogen-activated protein kinase), Notch1, PI3K (phosphoinositide 3-kinase)-mTOR (mechanistic target of rapamycin), and ER (estrogen receptor) signaling pathways often conferred resistance to this selection of drugs. Activation of the Notch1 pathway promoted acquired resistance to tamoxifen (an ER-targeted therapy) in serially passaged breast cancer xenografts in mice, and treating mice with a γ-secretase inhibitor to inhibit Notch signaling restored tamoxifen sensitivity. Markers of Notch1 activity in tumor tissue correlated with resistance to tamoxifen in breast cancer patients. Similarly, activation of Notch1 signaling promoted acquired resistance to MAPK inhibitors in BRAF(V600E) melanoma cells in culture, and the abundance of Notch1 pathway markers was increased in tumors from a subset of melanoma patients. Thus, Notch1 signaling may be a therapeutic target in some drug-resistant breast cancers and melanomas. Additionally, multiple resistance pathways were activated in melanoma cell lines with intrinsic resistance to MAPK inhibitors, and simultaneous inhibition of these pathways synergistically induced drug sensitivity. These data illustrate the potential for systematic identification of the signaling pathways controlling drug resistance that could inform clinical strategies and drug development for multiple types of cancer. This approach may also be used to advance clinical options in other disease contexts. (Copyright © 2014, American Association for the Advancement of Science.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu